Sökning: onr:"swepub:oai:DiVA.org:liu-193411" >
Renal Recovery for ...
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
-
- Cortazar, Frank B. (författare)
- St Peters Hosp Albany, NY 12209 USA
-
- Niles, John L. (författare)
- Massachusetts Gen Hosp, MA USA
-
- Jayne, David R. W. (författare)
- Univ Cambridge, England
-
visa fler...
-
- Merkel, Peter A. (författare)
- Univ Penn, PA USA
-
- Bruchfeld, Annette (författare)
- Karolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US,Karolinska Inst, Sweden; ChemoCentryx Inc, CA USA
-
- Yue, Huibin (författare)
- ChemoCentryx Inc, CA USA
-
- Schall, Thomas J. (författare)
- ChemoCentryx Inc, CA USA
-
- Bekker, Pirow (författare)
- ChemoCentryx Inc, CA USA
-
visa färre...
-
(creator_code:org_t)
- ELSEVIER SCIENCE INC, 2023
- 2023
- Engelska.
-
Ingår i: KIDNEY INTERNATIONAL REPORTS. - : ELSEVIER SCIENCE INC. - 2468-0249. ; 8:4, s. 860-870
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cyto-plasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR <= 20 ml/min per 1.73 m2. Methods: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups. Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR <= 20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was $2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group. Conclusion: Among patients with baseline eGFR <= 20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- ANCA-associated vasculitis; avacopan; complement; complement 5a receptor; low eGFR; renal recovery
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas